trial

Neuropsychological Assessment of Remediation for Cognitive Impairments in Schizophrenia

NCTId NCT04608032
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Unknown
Enrollment 70 (estimated)
Sponsored by Centre hospitalier de Ville-Evrard, France
Primary completion 2024-12-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Unknown
Enrollment
70 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2020-09-08
Primary completion
2024-12-01
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Recovery-Oriented Therapy

Sponsors

Centre hospitalier de Ville-Evrard, FranceLead Sponsor

Investigators

1
Clémence ISAAC, PHDPrincipal Investigator

Sites

2 total
Neuilly-sur-Marne, FranceNeuilly-sur-Marne, France

Facts & assertions

4 sourced
Enrollment
70
Phase
NA
Primary Completion Date
2024-12-01
Status
UNKNOWN
relationships
The graph out of here
drug
Recovery-Oriented Therapy
drug
lead_sponsor
Centre hospitalier de Ville-Evrard, France
company
indication
Schizophrenic Disorders
indication
Schizophrenia
indication
investigator
Clémence ISAAC, PHD
person